Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations

被引：0
|
作者：
Ros Montana, F. J. [1 ]
Navarro, V. [2 ]
Comas, R. [2 ]
Landolfi, S. [3 ]
Ramirez, L. [4 ]
Palmer, H. G. [1 ]
Garcia Rodriguez, A. [1 ]
Saoudi Gonzalez, N. [1 ]
Baraibar Argota, I. [1 ]
Rodriguez Castells, M. [5 ]
Salva Ballabrera, F. [6 ]
Tabernero, J. [7 ]
Elez Fernandez, M. E. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[2] Vall dHebron Inst Oncol VHIO, Oncol Data Sci ODysSey Grp, Cellex Ctr, Barcelona, Spain
[3] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain
[4] Vall dHebron Inst Oncol VHIO, Stem Cells Lab, Cellex Ctr, Barcelona, Spain
[5] Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Cellex Ctr, Barcelona, Spain
[6] Vall dHebron Univ Hosp, Med Oncol Gastrointestinal Unit, Barcelona, Spain
[7] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1817
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
626P
引用
收藏
页码：S447 / S447
页数：1
相关论文
共 50 条
  • [31] Targeting specific metabolic gene in BRAF V600E-mutated colorectal cancer
    Nishida, Naohiro
    Yukimoto, Ryohei
    Takeda, Mitsunobu
    Sekido, Yuki
    Hata, Tsuyoshi
    Wada, Noriko
    Hamabe, Atsushi
    Ogino, Takayuki
    Miyoshi, Norikatsu
    Uemura, Mamoru
    Yamamoto, Hirofumi
    Satoh, Taroh
    Doki, Yuichiro
    Eguchi, Hidetoshi
    CANCER SCIENCE, 2025, 116 : 1354 - 1354
  • [32] THE IMPACT OF BRAF V600E MUTATION AND MICROSATELLITE INSTABILITY ON OVERALL SURVIVAL (OS) IN METASTATIC COLORECTAL CANCER (MCRC)
    Parikh, A.
    Li, B.
    Lamarre, N.
    Abraham, A.
    Parzynski, C.
    Vieira, M. C.
    VALUE IN HEALTH, 2022, 25 (07) : S463 - S463
  • [33] Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation
    Zaina T. Al-Salama
    Drugs, 2021, 81 : 849 - 856
  • [34] Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation
    Al-Salama, Zaina T.
    DRUGS, 2021, 81 (07) : 849 - 856
  • [35] Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor plus antiEGFR plus /- MEK inhibitor
    Ros Montana, F. J.
    Martini, G.
    Villacampa Javierre, G.
    Baraibar, I.
    Comas, R.
    Garcia, A.
    Salva, F.
    Saoudi Gonzalez, N.
    Ciardiello, D.
    Toledo, R. D. A.
    Martinelli, E.
    Ciardiello, F.
    Vivancos, A.
    Palmer, H. G.
    Dienstmann, R.
    Tabernero, J.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2021, 32 : S556 - S556
  • [36] BRAF plus EGFR plus /- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer
    Ambrosini, Margherita
    Tougeron, David
    Modest, Dominik
    Guimbaud, Rosine
    Kopetz, Scott
    Decraecker, Marie
    Kim, Stefano
    Coutzac, Clelia
    Perkins, Geraldine
    Alouani, Emily
    Marmorino, Federica
    Pernot, Simon
    Sinicrope, Frank A.
    Elez, Elena
    Parent, Pauline
    Cremolini, Chiara
    Pietrantonio, Filippo
    Lonardi, Sara
    Gallois, Claire
    Taieb, Julien
    EUROPEAN JOURNAL OF CANCER, 2024, 210
  • [37] The role of Systemic Inflammation Score (SIS) in BRAF(V600) mutant metastatic colorectal cancer (mCRC).
    Martinez Lago, Nieves
    Covela Rua, Marta
    Brozos, Elena
    Fernandez Montes, Ana
    de la Camara Gomez, Juan
    Mendez Mendez, Carlos
    Jorge Fernandez, Monica
    Cousillas Castineira, Antia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Association of MSS/MSI-RNF43 molecular subtypes and clinical outcome of metastatic BRAF-V600E colorectal cancer patients treated with anti-BRAF/EGFR ± combinatorial therapies
    Elez, E.
    Ros, J.
    Randon, G.
    Lonardi, S.
    Cremolini, C.
    Pietrantonio, F.
    Tabernero, J.
    Toledo, R.
    ANNALS OF ONCOLOGY, 2022, 33 : S382 - S382
  • [39] Challenges in patient selection for surgical options in V600E BRAF-mutated metastatic colorectal cancer.
    Maddalena, Giulia
    Perissinotto, Eleonora
    Intini, Rossana
    Morris II, Van K.
    Bergamo, Francesca
    Newhook, Timothy E.
    Lonardi, Sara
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 280 - 280
  • [40] Identification of molecular determinants of vinorelbine resistance in BRAF(V600E) mutated chemorefractory metastatic colorectal cancer patients
    Vecchione, Loredana
    Beumer, Ines
    Mulero-Sanchez, Antonio
    Snel, Mireille
    Pietrantonio, Filippo
    Cremolini, Chiara
    Loupakis, Fotios
    Martinetti, Antonia
    Fuca', Giovanni
    Moretto, Roberto
    Fontanini, Gabriella
    Fassan, Matteo
    Lonardi, Sara
    Schirripa, Marta
    Keilholz, Ulrich
    Bernards, Rene'
    CANCER RESEARCH, 2018, 78 (13)
12345